---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-110537"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:38:29.580214+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure

## Summary
- Stock closed below $1.00 for 32 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- 180-day compliance period ends April 15, 2024; must close at $1.00 for 10 consecutive business days.
- If not cured, company may be eligible for another 180-day period if it meets other listing standards.
- Company intends to monitor bid price and evaluate options, including reverse stock split.
- Failure to regain compliance could lead to delisting from Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-23-110537
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923110537/0001104659-23-110537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923110537/tm2328605d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-110537
- JSON: https://secwatch.observer/filing/0001104659-23-110537.json
- Plain text: https://secwatch.observer/filing/0001104659-23-110537.txt

## Key facts
- Listing & Compliance Notices
  Outlook Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: October 16, 2023, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accorda
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923110537/0001104659-23-110537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.